Notícias e Atividades da Synthekine

Veja o organograma con seus 30 executivos principais

Biografias mais buscadas da Synthekine

• Debanjan Ray, Chief Executive Officer
• Pablo Cagnoni, Director
• Julie Grant, Director

Recentes movimentos de executivos em Synthekine

• Iris Sison, ingressou na Companhia como Vice President, Clinical Development Operations  (Notícia publicada em 24 de fevereiro de 2026).
• John Orwin, ingressou na Companhia como Chairman of the Board  (Notícia publicada em 24 de fevereiro de 2026).
• Srinivas Akkaraju, Director, deixou a Companhia  (Notícia publicada em 24 de fevereiro de 2026).

Criar um alerta
para seguir os movimentos de executivos da Synthekine.

Synthekine possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Synthekine

• Synthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK-012 in First-Line Non-Squamous NSCLC in Oral Presentation at AACR 2026 | Synthekine
• Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK 012 in First Line Nonsquamous NSCLC with Features of Immunotherapy Resistance | Synthekine
• Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors | Synthekine
• 2026 | Synthekine
• Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer | Synt
• First Patient Dosed in SYNERGY-101, a Global, Randomized Phase 2 Clinical Trial of STK-012 in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer | Synthekine
• Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer | Synthekine
• 2025 | Synthekine
• Synthekine Announces Late-Breaking Oral Presentation of Initial Clinical Data of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous NSCLC at SITC 2025 Annual Meeting | Synthekine
• Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting | Synthekine
• View more press releases Close

Redes sociais sobre Synthekine

• Synthekine na Wikipedia, Google News e Yahoo Finance
• Synthekine na LinkedIn, X (Twitter) e YouTube